About IMI

The AETIONOMY project is supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU) under grant agreement Number 115568, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

The AETIONOMY project is funded by the Innovative Medicines Initiative (IMI), a large-scale public- private partnership between the European Union and the pharmaceutical industry association EFPIA.

IMI aims to boost biopharmaceutical innovation in Europe and to speed up the development of better and safer medicines for patients. Through its unique and innovative funding scheme, IMI supports research projects in the areas of safety and efficacy, knowledge management and education and training.

The goal of the Innovative Medicines Initiative 2 (IMI 2) programme is to develop next generation vaccines, medicines and treatments, such as new antibiotics. It will build on the successes and lessons learnt under IMI's first phase. As before, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe’s growing health challenges, and secure the future international competitiveness of Europe’s pharmaceutical industry.

More information: http://www.imi.europa.eu/content/imi-2

"The AETIONOMY project has been mentioned in the IMI-2 future topic call text with the title "Linking clinical neuropsychiatry and quantitative neurobiology". The AETIONOMY industry coordinator Dr. Phil Scordis and the academic deputy coordinator Prof. Hofmann-Apitius declare hereby, that the AETIONOMY project will collaborate with the winning consortium that is being selected by independent reviewers. AETIONOMY as a project welcomes the opportunity to work more closely with colleagues from clinical neuropsychiatry and will start interacting with the successful consortium immediately after the start of the new project".